U.S. Food and Drug Administration The U.S. Food and Drug Administration approves the daraxonrasib drug as a treatment for metastatic pancreatic cancer, making it the first RAS inhibitor drug to be approved for the disease. This came after a previous study showed that it nearly doubled the survival rate for patients compared to chemotherapy. Sources: Reuters The Guardian